This site is intended for healthcare professionals only

This promotional information has been initiated, created, funded and reviewed by AstraZeneca. This webpage is intended for UK Healthcare Professionals only. By navigating away from the current page, you will be leaving an AstraZeneca sponsored resource webpage hosted on DiabetesontheNet.

Introducing the BYDUREON BCise® (exenatide 2 mg prolonged-release suspension for injection in pre-filled pen) device,1 to improve glycaemic control in adults with type 2 diabetes in combination with other glucose-lowering drugs.

Once-weekly Bydureon BCise® comes in a single dose pen with a hidden needle allowing for simpler administration than the Bydureon (exenatide 2 mg) dual chamber pen device.2

Administration of BYDUREON BCise® involves three simple steps with no need to see or handle a needle:

  1. Prepare
  2. Mix
  3. Inject

introduction

Get to know the BYDUREON BCise® device

If you would like to receive a sample BYDUREON BCise® (exenatide) device, please provide your preferred delivery address in the form below.

Your personal details will be collected by OmniaMed on behalf of AstraZeneca for the sole purpose of processing your request by mail.  Please click here to view the AstraZeneca privacy policy.

A practical guide

Click below to view a video introducing the BYDUREON BCise device® and demonstrating its use

Frequently asked questions

Click below to view a video discussing frequently asked questions about the BYDUREON BCise® device.

Test your knowledge

Do you know the BYDUREON BCise® device?

Test your knowledge of the BYDUREON BCise device and download a certificate of completion
  1. Bydureon Bcise (exenatide) SmPC. Available from: https://www.medicines.org.uk/emc/product/11085 Last Accessed March 2021
  2. Bydureon (exenatide) Dual Chamber Pen. SmPC (discontinued). Available from: https://www.medicines.org.uk/emc/product/3650/smpc Last Accessed March 2021

This promotional information has been initiated, created, funded and reviewed by AstraZeneca. This webpage is intended for UK Healthcare Professionals only. By navigating away from the current page, you will be leaving an AstraZeneca sponsored resource webpage hosted on DiabetesontheNet.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com or by calling 0800 783 0033.

Job code: GB-22319

Date of preparation: March 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.